Navigation Links
Quest Diagnostics Announces Final Tender Offer Results
Date:6/17/2009

MADISON, N.J., June 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer to purchase up to $200 million total aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are described in the Offer to Purchase, dated May 19, 2009 and related Letter of Transmittal.

The table below identifies the principal amount of each series of Notes validly tendered and the principal amount of each series that Quest Diagnostics has accepted for purchase, as well as the relevant proration factor for each series of Notes. The amount of Notes accepted was determined in accordance with the Acceptance Priority Level shown in the table below, subject to the Tender Cap.



                         Aggregate   Accept-
                         Principal    ance     Principal  Principal
     CUSIP    Title of    Amount    Priority    Amount     Amount   Proration
     Number   Security  Outstanding  Level     Tendered   Accepted   Factor
    --------- -------- ------------ ------- ------------ ------------ -----
    74834LAK6  5.125%  $400,000,000    1    $173,637,000 $173,637,000  N/A
              Senior
             Notes due
                2010

    74834LAE0   7.50%  $275,000,000    2     $48,720,000  $26,363,000 54.141%
               Senior
             Notes due
                2011

Settlement of the tender offer is expected to occur on June 18, 2009.

Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and Mit
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... dental biomaterial market will grow moderately through 2023 ... procedures and growing awareness of dental biomaterials all spur ... markets such as China and ... will bring dental procedures within reach for a larger ...
(Date:12/17/2014)... NY (PRWEB) December 16, 2014 The ... changes since 2013, which is why IBISWorld updated its ... industry continues to benefit from an intensified focus on ... proposal for new emission standards for power plants and ... operators. According to IBISWorld Industry Analyst Sarah Kahn, “a ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" ... high-quality,pharmaceutical grade glucose products in China, today announced ... months ended September 30, 2008,after the close of ... will conduct a conference call on Friday, November ...
... class drug illustrates early signal of transport of ... Exchange Symbol: RVX CALGARY, Nov. 10 /PRNewswire-FirstCall/ ... with its lead drug,RVX-208, a first in class ... Phase 1a clinical trial found that treatment with ...
... Overall Survival, Summary: Three ofatumumab Abstracts Have Been Accepted for ... ... Genmab A/S (OMX: GEN),announced today that three ofatumumab (HuMax-CD20(R)) ... of Hematology Annual,Meeting and Exposition (ASH) December 6-9, 2008. Updated ...
Cached Biology Technology:Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 2Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 3
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... By studying mice with skin cancer, researchers at the Huntsman ... to inhibit a mutant gene found in up to 30 ... this gene are important in cell signaling, or communication among ... gene that has been shown to promote the growth of ...
... when and where certain proteins are made is crucial ... proteins, information from DNA is transcribed into RNA molecules ... of proteins. But not all genes code for proteins--some ... interfere with--and therefore control--the production of proteins. A new ...
... partially differentiated stem cells with gene therapy can promote the ... spinal cords of rats, a new study shows. The treatment, ... improves the animals' motor function and electrical conduction from the ... to new ways of treating spinal cord injury in humans. ...
Cached Biology News:Scientists inhibit cancer gene 2MicroRNAs play a big part in gene regulation - and evolution 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Biology Products: